PDC Promises: Japanese Startup Fills Pharma’s Pipelines With Peptide-Drug Conjugates

08 Feb 2018

Originated from Tokyo University, drug discovery firm PeptiDream recently competes pre-clinical study for its anti-flu peptide PD-001, after signing 17 deals with large drug makers in 11 years. The company's CEO Patrick Reid outlines to Scrip prospects of peptide-drug conjugates (PDCs) and discovery strategy.

Kanagawa, Japan-based biotech startup PeptiDream Inc. has signed licensing deals with many multinational drug makers, 17 in total in 11 years, courting Roche's Genentech, Janssen Pharmaceuticals Inc. and Shionogi & Co. Ltd., among others.

The key to this track record is its proprietary Peptide Discovery Platform System (PDPS) platform, in particular, peptide-drug conjugates (PDCs),...